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The effect of L-PRF membranes on 
bone healing in rabbit tibiae bone 
defects: micro-CT and biomarker 
results
Fernanda Faot1, Sanne Deprez2, Katleen Vandamme2, Germana V. Camargos3, Nelson Pinto4, 
Jasper Wouters5, Joost van den Oord5, Marc Quirynen6 & Joke Duyck2
More insight into the biological fundamentals of leukocyte platelet-rich fibrin (L-PRF) guided healing 
is necessary to recommend its application, in particular in deficient bone sites that need to support 
implants. This study investigated the short-term bone healing effect of L-PRF treatment in cylindrical 
non-critical sized bone defects with 3 mm diameter and 6 mm depth in tibiae of 18 adult male New 
Zealand White rabbits. After a randomization process, 96 bone defects were prepared and half of them 
were filled with a L-PRF membrane, while untreated defects in the opposite tibia served as control 
group. The rabbits were euthanized after 7, 14 or 28 days of healing. The bone healing of the cortical 
and medullary areas was investigated by micro-CT, while the expression of molecular markers (RUNX2, 
VEGFA, COL1A2 and BMP2) was assessed by qRT-PCR. Treatment with L-PRF did not affect the micro-
structural bone characteristics of the repaired bone tissue, except for a decrease in the trabecular 
connectivity at the cortical level after 14 days of healing. At this time, RUNX2 and VEGFA mRNA levels 
were significantly lower in the treated defects. L-PRF membranes thus had a temporary negative 
influence on the bone microarchitecture (Tb.Pf) and on the RUNX2 and VEGFA expression during early 
bone healing. Overall, L-PRF treatment did not enhance bone regeneration in these non-critical size 
defects after 28 days.
In many cases involving extended periods of tooth loss, alveolar bone grafting is required before or during oral 
implant placement. Sinus lift techniques and socket preservation procedures require biomaterials capable of 
inducing fast and effective wound healing and bone regeneration1. Since autologous bone grafting is associated 
with considerable morbidity and the single use of biomaterials still requires long healing processes2, platelets 
concentrates are intensively investigated as an alternative method for improved bone regeneration3.
Platelet rich fibrin (L-PRF) was first described by Choukroun et al. (2001), and has been referred to as a sec-
ond generation platelet concentrate4. Fibrin is a natural guide for angiogenesis, traps the circulating stem cells5 
and provides wound protection by epithelial coverage6,7. The fibrin matrix of L-PRF is obtained as a result of slow 
polymerization. This matrix can hold many growth factors and cytokines, and can release them in the wound site 
for prolonged times8.
The growth factors present in L-PRF have been shown to accelerate bone repair and to promote fibroblast 
proliferation9. In addition, these factors increase tissue vascularity, the rate of collagen formation, and mitosis of 
mesenchymal stem cells, endothelial cells and osteoblasts9. Several authors have also demonstrated that a fibrin 
matrix provides an optimal support for mesenchymal stem cells6,10,11, which contribute to regeneration of osseous 
defects and of many other tissues. As a consequence of all these powerful effects on tissue regeneration, a growing 
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number of human clinical studies have confirmed the beneficial effect of the use of growth factors via L-PRF 
application in reconstructive oral and maxillofacial surgery12, including periodontal surgery13–16 implants17 and 
sinus grafting18,19.
So far, studies that investigated the biologic events in the early stages of L-PRF -mediated bone healing are 
limited and restrict to the cortical bone2,20. Most studies involved the use of L-PRF for soft tissue repair21, while 
the use of its fibrin-based material solely as a filling material for large bone defects remains controversial. One 
study22 reported positive effects of L-PRF when used in conjunction with titanium barriers. L-PRF use in the 
latter case increased the quality of the newly formed bone and enhanced the rate of bone formation, attributed to 
the concentration of growth factors. Kim et al.1 also reported increased bone mineral density and bone volume 
in calvaria bone defects of rabbits treated with PRF already after 6 weeks. These results were similar to two other 
platelets concentrates tested: PRP and Concentrated Growth Factor. Cho et al.23 reported a positive bone healing 
effect of L-PRF on bone integration (higher bone density) of oral implants installed at 4 weeks after preparing 
bone defects in rabbit tibias, using removal torque measurements. The animal study conducted by Knapen et al.2 
on the other hand, showed that L-PRF did not provide any additional effect on the kinetics, quality and quantity 
of bone during guided bone regeneration over a period of 12 weeks.
The present study aimed to evaluate the effect of L-PRF on the early stages of bone healing using an in vivo 
rabbit model. The study was set up to test the hypothesis that the treatment of non-critical sized bone defects by 
L-PRF application enhances the bone healing dynamics. Bone repair was investigated with or without L-PRF 
membranes applied in non-critical sized long bone defects in rabbits using microCT, after healing periods of 7, 
14 and 28 days. Expression of molecular markers for bone healing, BMP2, RUNX2, VEGFA and COL1A2, was 
assessed by qRT-PCR.
Methods
Experimental design. The study was designed as a randomized test-control study. Eighteen male New 
Zealand White Rabbits weighing between 3 and 4 kg were selected for this study. The number of animals required 
was estimated on the basis of previous studies1,2,24. A minimum of 12 samples (bone defects) was needed to detect 
a difference between 2 groups (power of 80% and an error probability of 5%). Our study considered 16 as the 
sample size of each group (with or without L-PRF membranes) resulting in 6 samples to be evaluated according to 
the periods of time: 7, 14 and 28 days. We also planned our experimental design taking in account the Effect Size 
evaluation, once we adopted the animal as its own control. Effect sizes found in laboratory studies are normally 
high, especially in paired studies, since the intra-animal variation is likely less than the inter-animal variation. To 
achieve this, 18 rabbits were divided into 3 groups and each rabbit should receive at least 4 bone defects (2 L-PRF, 
2 control) for CT and molecular analysis, respectively. The observed effect sizes ranged between 0 and 1.9, and our 
study detects large effect sizes of 1.8 with 80% confidence, at the conventional significance level of 5%.
The experimental protocol was approved by the KU Leuven University Committee on Use and Care of 
Animals. All methods in this study were performed in accordance with the relevant guidelines and regulations 
as provided by this committee. The manuscript was prepared according to ARRIVE guidelines25. The rabbits 
were kept in separate cages and their diet consisted of standard rabbit food pellets and water, available ad libitum. 
They were housed in a room maintained at 24 °C with a 12-h light/dark cycle. The animal’s weight was monitored 
weekly. A total of 36 bilateral tibias were randomized taking in account the test and control sides, as well as, the 
bone defect position for the microCT and qRTPCR analysis.
The bone defects were left to heal for 7, 14 or 28 days (n = 6 for each healing time point). In total, 48 samples 
were created for each condition. The 12 rabbits where the defects were allowed to heal for 7 or 14 days received 6 
bone defects: 3 test defects in one tibia and 3 control defects in the other tibia. The 6 remaining rabbits of the 28 
days healing period received only 4 defects (2 per tibia). Per rabbit a test and control sample were intended for 
micro-CT and histological analyses. Micro-CT analysis was performed in 6 samples of each group to evaluate 
the bone micro-architecture of control and test defects at the mentioned healing times. qRT-PCR analysis was 
performed only for the 7 and 14 days healing to investigate the expression of genes that are typically expressed 
during the early bone healing.
Bone defect preparation. After uncovering the medial part of the proximal diaphysis of both tibiae, 2 
or 3 cylindrical bone defects were drilled in both tibiae. In one tibia, the defects were filled with L-PRF (test 
defects) whereas the defects in the contralateral tibia remained unfilled (control defects). The bone defects were 
made using a 3-mm trephine bur (Medicon CMS, Tuttlingen, Germany), thereby creating 3-mm wide cylindri-
cal defects. The drill perforated the medial cortex and was inserted until it touched the inner side of the lateral 
cortex resulting in a defect length of approximately 6 mm. Each tibia received several bone defects (2 or 3), with 
10 mm inter-distance (measured between the centers of the bone defects) (Fig. 1). The skin was sutured (Vicryl 
3/0, Ethicon, Johnson and Johnson, USA) and the animals were given 0.015 mg/kg of buprenorphine (Vetergesic, 
Ceva, Belgium) as pain relief. The bone defects were left to heal for 7, 14 or 28 days.
L-PRF membrane preparation. For each L-PRF membrane, 10 ml of blood was collected from the central 
vein of the rabbit ear with a syringe, transferred 2 aliquots of 5 ml to plastic tubes and immediately centrifuged 
in a small laboratory centrifuge (Model EBA 20, Andreas Hettich GmbH&Co. KG). The standard centrifugation 
parameters were 2700 RPM for a period of 12 minutes4. This protocol was able to successfully produce L-PRF 
(Fig. 2), as observed in the pilot study. The L-PRF clot was subsequently compressed with a glass plate for 4 min-
utes, and 2 L-PRF membranes were produced with similar dimensions26. Prior to filling the defect, the L-PRF 
membrane was wrapped and the leucocyte-rich blood interface was exposed in order to be positioned inside of 
the cavity in contact with the bone defect walls.
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Post-operative monitoring. After surgery, all the animals were housed at room temperature 18 ± 3 °C and 
relative humidity (55 ± 15%). The feeding condition, weight, body temperature, breathing, appearance of surgical 
site, the possibility of incision infection, the movement function (animal’s ability to ambulate and perform nomal 
body movements), pain and distress of rabbits were monitored daily during the first week, each 3 days during the 
second week and weekly after the third week until the study completion.
Specimen preparation for micro-X-ray computed tomography analysis. After euthanizing the 
animals with an i.v injection of 2 mL of T61 (embutramide-mebenzoniumjodide-tetracaine HCl solution), the 
tibia skin was excised and the defect sites were removed along with surrounding bone tissue, and immediately 
fixated in 10% CaCO3–buffered formalin solution (pH 7.4) at 4 °C for 48 h. The samples were then preserved in 
70% ethanol at 4 °C in attendance of the micro-X-ray computed tomography (μ CT) scanning. One control and 1 
test sample per rabbit was used for micro-CT analysis.
To assess the bone micro-architectural changes in response to L-PRF membrane application (test) compared 
to no L-PRF application (control), 1 test and 1 control sample were examined ex vivo using a Skyscan 1172 μ CT 
system (Bruker, Kontich, Belgium). During scanning, the tibia was protected by a parafilm pellicle and immo-
bilized onto the sample supporter by means of a soft modeling clay. The bone samples were scanned along the 
longitudinal planes in the medial and lateral regions to obtain the μ CT images. The following scanning parame-
ters were used: 14.1 μ m pixel size, 50 kV X-ray voltage, 200 μ A electric current and 0.5 mm Al filter. The scanning 
resulted in reconstructed 3D data sets with a voxel size of 14.1 μ m, which were subsequently explored in the 
Dataviewer software and quantified using a CTAn automated image analysis system (Bruker, Kontich, Belgium) 
(Fig. 3A). Volumes of interest were defined at trabecular and at cortical level as detailed below. The morphometric 
parameters were calculated according to the methodology described by Bouxein and co-workers (2010)27.
To determine the volume of interest in the axial direction, the dimensions and shape of the bone defect were 
used as a reference to localize the regenerated area. For the morphometric analysis, a subregion of the original 
dataset was selected for a representative measurement. The selected region of interest (ROI) included the whole 
defect area containing the newly formed bone (Fig. 3B). By auto-interpolation between layers, the ROI became 
the volume-of-interest (VOI), which is the essential basis for the 3D quantitative analysis. A VOI with a rectangu-
lar shape was determined in the transaxial plane with a fixed width of 3 mm and 2 different height dimensions: the 
VOI for the cortical area was 1 mm, whereas the height of the VOI rectangle for the medullary area was between 5 
and 6 mm considering the distance between the outside surface of the medial cortical (i.e. site of the periosteum) 
and the inside surface of the lateral cortical bone (i.e. site of the endosteum). Images from the axial projection of 
the tibiae were taken, which resulted in 212 layers covering the whole defect. Within the VOI, the volume of the 
newly formed bone was calculated as a percentage. Based on the calculated histogram, the bone was defined to be 
in the 64–225 gray value range.
The following bone micro-structural parameters of newly formed bone were evaluated at both the cortical 
and trabecular (medullar) level: Bone volume (BV, mm3); Bone volume/Tissue volume (BV/TV, %); Bone Surface 
Figure 1. Surgical steps during bone defect creation and L-PRF insertion. (A) Tibia exposition; (B) Marking 
the planned bone defect areas; (C) Bone defect creation at 10 mm inter-distance (measured between the centers 
of the bone defects); (D) Bone defects filled with L-PRF membrane.
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(BS, mm2); Intersection surface (i.S, mm2); Bone surface/Volume ratio (BS/BV, mm−1); Trabecular pattern factor 
(Tb.Pf, mm−1); Structure model index (SMI); Degree of ansiotropy (DA); Fractal Dimension (FD). Furthermore, 
Tissue volume (TV, mm3); Tissue Surface (TS, mm2); Bone surface density (BS/TV, mm−1); Trabecular thickness 
(Tb.Th, mm); Trabecular separation (Tb.Sp, mm) and Trabecular number (Tb.N, mm−1) were also evaluated at 
the level of trabecular ROI.
RNA extraction, complementary DNA (cDNA) synthesis and quantitative real time PCR 
(qRT-PCR). After euthanizing the animals, bone defect samples for qRT-PCR were immediately harvested 
and submerged in a nontoxic tissue storage reagent (RNAlater solution, Thermo Scientific, USA) and were frozen 
at −20 °C for later processing. RNA was extracted from 24 samples of the 7 day and 14 day groups (12 samples 
per group; 1 test and 1 control sample from each rabbit) using the TRIzol reagent (Invitrogen, Thermo Fisher 
Scientific, Waltham, USA) according to manufacturer’s instructions. Briefly, bone samples were grinded in a mor-
tar with TRIzol reagent and incubated at room temperature for 5 minutes to lyse the cells. Chloroform was added 
to separate the samples into a phenolchloroform phase, an interphase, and an aqueous phase. The latter contains 
the RNA and was used for the RNA isolation step. RNA was precipitated by addition of isopropanol. The resulting 
precipitate was washed with ethanol and resuspended in RNase-free water. The concentration of purified RNA 
was measured on the NanoDrop ND-1000 Spectrophotometer (NanoDrop, Thermo Fisher Scientific)
cDNA was synthesized from 500 ng of RNA using Superscript II Reverse Transcriptase (RT) (SS II kit, 
Invitrogen). Briefly, 0.8X random primers (Invitrogen) and 0.8 mM deoxyribonucleotide triphosphates (dNTP 
mix, Invitrogen) were added and the samples were heated to 65 °C for 5 minutes and afterwards cooled on ice. 
During this cooling period, a mixture of 1x First Strand Buffer (Invitrogen), 0.01 M 1,4-dithio-DL-threitol (DTT), 
5% RNase OUT (Invitrogen) and 10 units of Superscript II RT was added. Lastly, the samples were heated to 25 °C 
for 10 minutes, 42 °C for 50 minutes and 70 °C for 2 minutes, to perform the subsequent steps of reverse transcrip-
tion. Afterwards, the samples were cooled on ice.
Gene expression levels were analysed using the qRT-PCR method. Rabbit-specific primer-probe sets were 
commercially acquired (TaqMan Gene Expression Assays, Applied Biosystems, Thermo Fisher Scientific) for 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH, Oc03823402_g1), β -actin (ACTB, Oc03824857_g1), 
Runt-related transcription factor 2 (RUNX2, Oc02386741_m1), bone morphogenetic protein 2 (BMP2, 
Oc03824113_s1), vascular endothelial growth factor A (VEGFA, Oc03395999_m1) and collagen type 1 alpha 2 
(COL1A2, Oc03396455_m1). TaqMan Gene Expression Master Mix 1x (Applied Biosystems) and cDNA (0.3 μ g) 
were added to the primer-probe mix. The procedure was completed using the 7900 HT Fast Real-Time PCR 
System (Applied Biosystems). The samples were heated to 50 °C for 2 minutes, then brought to 95 °C for 10 min-
utes, followed by 50 cycles of 15 seconds at 95 °C and 1 minute at 60 °C. During the last step of each cycle, the 
fluorescent signal was measured. Expression levels were analysed using the Δ Δ Ct method, after normalization 
against the pooled expression levels of housekeeping genes GAPDH and ACTB.
Statistical Analysis. Statistical analyses were performed using the SAS v. 9.0 software (SAS Institute, Inc, 
Cary, NC) and R v3.2.3 (R Core Team, Vienna, Austria) with a significance level fixed at 5%. The assumptions 
of equality of variances and normal distribution of errors were evaluated for each variable, and the data were 
logarithmically transformed when these assumptions were violated. The values of the microarchitectural param-
eters and mRNA expression levels were compared between test and control groups and within the groups for 
each healing period (7, 14 or 28 days) using 2-way ANOVA and 1-way ANOVA respectively, in order to assess 
the effect of the treatment and of the healing time, and their interactions with the cortical and medullar bone 
Figure 2. (A) L-PRF generated after centrifugation, the volume of 10 mL of blood collection was distributed in 
2 tubes; (B) 1. Squeezing of L-PRF clot; 2. L-PRF membrane; 3. Splitting the L-PRF membrane. (C) The L-PRF 
membrane before insertion into a cavity.
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micro-architectural response to the bone defect surgery. Post-hoc comparisons were done using the Tukey 
Honestly Significant Difference (HSD) test.
Results
There were no intra-operative clinical issues; post-operatively all rabbits regained independent feeding ability 
with normal gait, following recovery from anesthesia. All animals except 1 recovered from surgery without com-
plications and showed no signs of discomfort (apparent signs of infection such as a red, hot incision or exudate) 
during the healing process. One rabbit of the 7-days group fractured a tibia on the 3rd day post-surgery. The 
fracture did not involve a bone defect under investigation. The tibia was immobilized, the rabbit received intra-
muscular injection of buprenorphine (Vetergesic 0.3 mg/ml, dose: 0.05 ml/kg) as analgesic for 4 days, displayed 
no additional problems, and was sacrificed at day 7. Bone repair morphological characteristics in the cortical and 
medullary areas can be observed in Fig. 4.
The 2-way ANOVA results of the bone micro-architecture for the different healing periods and for the differ-
ent experimental conditions (L-PRF application or not) are shown in Table 1 for the cortical and the medullary 
region.
The healing time effect (i.e. 7, 14, and 28 days) was statistically significant for all structural parameters eval-
uated in the cortical and medullary area (ANOVA p < 0.05; Supplementary material), except for the trabecular 
volume (TV) and trabecular surface (TS) parameters. The results of the control versus L-PRF membrane group on 
the other hand indicate that the treatment did not affect the bone micro-structural parameters, neither at cortical 
nor at medullar level. The interaction between the independent variables healing time and treatment modality 
at the cortical bone repair site was positive for the parameter Tb.Pf. For the other cortical level parameters, no 
interaction was found. (ANOVA p < 0.05).
As expected, the duration of healing was the main factor that influenced the bone repair at the cortical level 
(Table 2). The variables BV, BV/TV, Tb.Pf, SMI and FD for the repaired cancellous bone showed a statistically sig-
nificant increase (p < 0.05) after 28 days of healing compared to the other evaluated healing time points. Statistical 
differences were found between the control group and L-PRF treatment after 14 days of healing only for the Tb.Pf 
Figure 3. (A) Bone defect localization in the 3 planes orientation to explore bone defect (Data viewer software, 
Bruker, Kontich, Belgium); (B) Regions of interest analyzed: ROI 1 (Cortical area, 3 × 1 mm) and ROI 2 
(Medullary area 3 × 5.2 mm).
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parameter (p = 0.04) with higher values for the L-PRF treatment. Between 14 and 28 days, the DA and FD values 
decreased significantly (p < 0.05). Finally, significant lowest BV, BS/TV, BS and i.S values (p < 0.05) were observed 
after 7 days healing.
Also at the medullar level, the time of healing was the main factor influencing the bone repair (Table 2). For 
all medullar level parameters, no interaction was found between the time of healing and the treatment type. 
Unlike in the cortical area, most of the parameters reached significant highest values after 14 days of healing: BV 
(p < 0.0001); BV/TV (p < 0.0001); BS (p < 0.0001); BS/BV (p < 0.0001); BS/TV (p < 0.0001); Tb.N (p < 0.0001) 
and i.S (p = 0.0075), while Tb.Th (p < 0.0001), Tb.Sp (p < 0.0001) and DA (p = 0.0001) the significant lowest 
values for the 14 days healing time point. After 7 days healing time, the Tb.Pf parameter showed the significantly 
lowest value (p < 0.0001), while the SMI parameter was significantly highest (p < 0.0001). After a 28 days healing 
period, significantly highest values were only found for the FD parameter (p = 0.0013).
The qRT-PCR results are shown in Fig. 5. After 7 days of healing time, no significant differences in expression 
levels were observed between the L-PRF-treated defect and the control defect. After a healing period of 14 days, 
the expression levels of RUNX2 and VEGFA were significantly decreased in the treated site compared to the 
control site.
Figure 4. Bone repair morphological characteristics in the cortical and medullary areas according to the 
healing times. 
Healing time Treatment BV (mm3) BV/TV (%) BS (mm2) BS/BV (mm−1) BS/TV (mm−1) i.S (mm2) Tb.Pf (mm−1) SMI DA FD
28 days
Control 5.20  (± 0.85) A
58.33  
(± 9.61) A
77.85 
(± 21.59) A
14.97  
(± 3.64) A
8.73  
(± 2.43) A
17.55  
(± 1.41) A
− 11.44  
(± 6.82) A
− 2.01  
(± 1.37) A
1.57  
(± 0.27) B
2.75  
(± 0.05) A
L-PRF 5.38  (± 1.60) A
60.47  
(± 17.96) A
70.30  
(± 12.13) A
13.94  
(± 4.25) A
7.90  
(± 1.36) A
17.10  
(± 1.54) A
− 10.07  
(± 2.94) A
− 2.38  
(± 2.01) A
1.83  
(± 0.77) B
2.76  
(± 0.07) A
14 days
Control 2.39  (± 0.74) B
26.90  
(± 8.28) B
86.33  
(± 45.48) A
33.78  
(± 10.72) B
9.70  
(± 5.11) A
11.85  
(± 1.79) B
8.81  
(± 3.92) B a
2.92  
(± 0.74) B
1.30  
(± 0.16) A
2.54  
(± 0.05) C
L-PRF 2.04  (± 0.43) B
22.92  
(± 4.88) B
72.65  
(± 22.12) A
34.98  
(± 3.62) B
8.15  
(± 2.46) A
10.84  
(± 1.64) B
16.38  
(± 1.82) B b
3.98  
(± 0.44) B
1.19  
(± 0.08) A
2.47  
(± 0.01) C
7 days
Control 1.44  (± 0.19) C
16.17  
(± 2.12) B
20.18  
(± 1.91) B
14.12  
(± 1.00) A
2.27  
(± 0.21) B
9.74  
(± 1.10) C
9.12  
(± 4.00) B
3.21  
(± 0.79) B
1.71  
(± 0.23) B
2.59  
(± 0.06) B
L-PRF 1.43  (± 0.17) C
16.13  
(± 1.90) B
19.97  
(± 2.48) B
13.93  
(± 0.89) A
2.24  
(± 0.28 ) B
9.92  
(± 0.99) C
7.75  
(± 4.37) B
2.93  
(± 1.29) B
1.71  
(± 0.20) B
2.61  
(± 0.04) B
Table 1.  Results of μCT analysis of bone regeneration at cortical bone level for L-PRF-treated and control 
groups, in function of healing time. Different capital letters within the same column indicates statistical 
significant differences between the healing time groups, irrespective to the treatment applied. Different lower 
case letters indicate the statistical significant differences found between the untreated (control) and treated  
(L-PRF) groups (p = 0.044).
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Discussion
Taken the results together, the hypothesis that the application of L-PRF in non-critical sized bone defects 
enhances the bone healing dynamics was rejected. Although the qRT-PCR results show a difference on the mRNA 
level after 14 days, this difference did not result in a change of the outcome.
L-PRF is in essence a fibrin matrix in which platelets, cytokines and cells are trapped and may be delivered 
within a certain time frame28. Clinically, the use of L-PRF includes advantages as ease of preparation and lack of 
biochemical handling of blood that makes this preparation strictly autologous. Furthermore, it provides adhe-
siveness and tensile strength for clot stabilization. Thus, its use as an autologous scaffold for periosteal cells and 
for osteoblasts has shown to be able to promote higher metabolic activity and cell proliferation6,29. These positive 
effects during wound repair are not related only to haemostasis, but also to the fact that it can provide a matrix for 
migration of tissue-forming cells like fibroblasts and endothelial cells, which are involved in tissue (re)modelling 
and angiogenesis.
Up to now, the potential for bone formation was only evaluated in calvaria2 bone defects, i.e. a cortical bone 
shell, or in tibia defects in combination with other materials2,24,30–32. Time points for monitoring the healing pro-
cess in the presence of L-PRF included periods longer than 4 weeks 1,2,33. However, the clinical beneficial effect of 
L-PRF on bone regeneration during the early stages of bone regeneration is largely unexplored. In the context of 
the limited information related to the role of L-PRF during early healing, our study evaluated the effect of L-PRF 
on the early stages of bone regeneration in non-critical sized bone defects, expecting enhanced healing dynamics 
compared to the normal wound-healing process. With this purpose, the osteoinductive properties of the L-PRF 
membranes, in contact with exposed cortical and medullary tissues of the tibiae of rabbits were investigated by 
microCT and qRT-PCR, for healing periods of 7, 14 and 28 days.
Our results indicate that the treatment of non-critical sized bone defects by L-PRF application did not sig-
nificantly enhance the healing dynamics, at least in terms of bone morphological parameters. The comparison 
between the control and the L-PRF membrane sites revealed that the treatment did not affect the micro-structural 
parameters neither in cortical nor in the medullary region, with the exception of a significantly higher bone 
trabecular parameter (Tb.Pf) in the 14-days L-PRF healing group compared with the control group. The higher 
Tb.pf values in the L-PRF group indicate a less favourable trabecular geometry developed in the first 2 weeks. 
The latter suggests an altering effect on bone repair, since a well-developed trabecular structure provides a rigid 
framework, and forms a good basis for further calcification. However, despite the fact that the trabecular struc-
ture in the L-PRF group improved at an accelerated rate between the 2nd and the 4th week, this morphological 
Healing 
time Treatment TV (mm3)
BV 
(mm3)
BV/TV 
(%) TS( mm2) BS (mm2)
BS/BV 
(mm−1)
BS/TV 
(mm−1)
Tb.Th 
(mm)
Tb.Sp 
(mm)
Tb.N 
(mm−1) i.S
Tb.
Pf(mm−1) SMI DA FD
28 days
Control 46.22  (± 11.07) A
3.67  
(± 1.79) B
9.02  
(± 6.90) B
79.35  
(± 14.66) A
51.38  
(± 30.11) B
13.78  
(± 3.32) B
1.27  
(± 1.12) B
0.36  
(± 0.08) A
2.02  
(± 0.59) A
0.26  
(± 0.22) B
13.57  
(± 5.68) B
2.78  
(± 2.67) B
2.17  
(± 0.89) B
2.79  
(± 1.79) A
2.65  
(± 0.05) A
L-PRF 47.48  (± 10.91) A
2.56  
(± 1.18) B
5.52  
(± 2.50) B
81.18  
(± 14.60) A
41.73  
(± 15.01) B
17.93  
(± 6.47) B
0.91  
(± 0.38) B
0.30  
(± 0.09) A
2.00  
(± 0.41) A
0.19  
(± 0.11) B
12.46  
(± 3.44) B
5.84  
(± 10.65) B
2.16  
(± 1.77) B
2.33  
(± 0.81) A
2.56  
(± 0.16) A
14 days
Control 43.72  (± 7.78) A
7.12  
(± 2.51) A
16.47  
(± 6.03) A
76.32  
(± 10.27) A
271.10  
(± 104.19) A
37.43  
(± 6.02) A
6.35  
(± 2.78) A
0.15  
(± 0.06) B
0.52  
(± 0.28) B
1.27  
(± 0.69) A
16.14  
(± 5.40) A
7.91  
(± 11.88) B
2.61  
(± 1.66) B
1.29  
(± 0.17) B
2.40  
(± 0.11) B
L-PRF 47.12  (± 11.16) A
7.78  
(± 2.10) A
16.98 (± 
4.86) A
80.70  
(± 14.87) A
318.83  
(± 103.91) A
40.82  
(± 8.08) A
7.18  
(± 3.20) A
0.16  
(± 0.07) B
0.60  
(± 0.42) B
1.40  
(± 0.95) A
19.37  
(± 4.45) A
3.35  
(± 6.33) B
2.00  
(± 0.63) B
1.22  
(± 0.07) B
2.45  
(± 0.08) B
7 days
Control 44.50  (± 4.06 ) A
2.2  
(± 0.59) B
5.08  
(± 1.41) B
77.20  
(± 5.43) A
57.03  
(± 55.07) B
23.88  
(± 18.86) B
1.36  
(± 1.46) B
0.28  
(± 0.11) A
1.58  
(± 0.74) A
0.24  
(± 0.20) B
11.06  
(± 2.86) B
26.55  
(± 13.07) A
7.16  
(± 2.28) A
1.96  
(± 0.65) A
2.39  
(± 0.22) B
LPRF 46.75  (± 4.17) A
2.93± 
(0.97) B
6.39  
(± 2.61) B
80.20  
(± 5.55) A
60.52  
(± 37.42) B
19.37  
(± 6.06) B
1.34  
(± 0.93) B
0.30  
(± 0.08) A
1.46  
(± 0.45) A
0.25  
(± 0.21) B
13.54  
(± 2.85) B
26.72  
(± 7.21) A
8.15  
(± 2.03) A
1.82  
(± 0.33) A
2.45  
(± 0.09) B
Table 2.  Results of μCT analysis of bone regeneration at medullar bone level for L-PRF-treated and 
control groups, in function of healing time. Different capital letters within the same column indicate statistical 
significant differences between the healing time groups, irrespective to the treatment applied.
Figure 5. mRNA expression levels of COL1A2, BMP2, RUNX2 and VEGFA. Data are represented as relative 
expression in L-PRF treated defect compared to control defect with values of the control defect set as 100% 
expression. (*p < 0.05, n = 6). qPCR analysis was not performed for samples of d28.
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parameter was not highly significant (p = 0.044) in the comparisons between control and test groups, and identi-
cal Tb.pf values were achieved in the end of the study in the control group. Based on the results of this study, we 
cannot determine whether this trend continues past 28 days.
The bone volumes in the experimental and control groups were similar after 14 and 28 days, although the 
study by Kim et al. found an increased bone volume with L-PRF in rabbit calvaria after 6 weeks1. Although 
improved bone volumes on short time frames were not found in the present study, it could be that the accelerated 
improvement of the trabecular connectivity in the L-PRF sites after 2 to 4 weeks of healing, continues beyond 4 
weeks healing time, thereby leading to improved bone regeneration with L-PRF after longer healing periods. One 
explanation for the lack of indications for L-PRF-mediated accelerated healing in this study is related to the type 
of the bone defect adopted in the present study. The performed defects were non-critical sized defects, implying 
that healing was expected to occur in either case. In addition, the morphology of the tibiae does not favour reten-
tion of the L-PRF clot during healing. Since the medullary area is a rather “hollow tube” that is highly vascular-
ised, and filled with soft tissues, the clot is mainly retained by the cortical bone walls. The long-term effect of the 
L-PRF membrane is difficult to estimate, although one study noted a slow release of growth factors for at least 7 
days8. In our study, we could also observe that the membrane was not fully resorbed after 14 days (Fig. 4), placing 
an upper limit on the residence time of the L-PRF clot.
According to Knapen et al.2, connective cells could be observed in the region of the osteotomy 1 week 
post-L-PRF application but did not extend into the L-PRF clot. After 5 and 12 weeks no benefits were described 
in terms of the rate of bone mineralization. So far, positive results for L-PRF are exclusively described in asso-
ciation with titanium barriers22, which likely improves the residence time of the L-PRF clots, or when a “critical 
sized defect” model is used1. In our study, the treated group at the 14 days healing time point showed a reduced 
trabecular connectivity.
Additionally, our study showed no positive effect of L-PRF on mRNA expression of some important factors in 
bone healing. Currently, no research has been conducted to investigate the effects of L-PRF on mRNA expression 
during the inflammatory process and bone regeneration in animals. In this study, we chose to investigate RUNX2, 
VEGFA, BMP2 and COL1A2 because they are the best-known factors involved in bone healing and can influence 
multiple pathways that are involved in the repair process. In addition, RT-PCR analysis in this small panel of 
molecular markers was performed in order to identify early subtle changes in gene expression and to investigate 
their physiological importance when L-PRF membranes are applied. Unfortunately, measuring the protein levels 
of the investigated growth factors was not possible due to the limited availability of sample tissue.
Our biomarker results showed no positive effect of L-PRF on mRNA expression, and contrary to what we 
expected, L-PRF application temporally resulted in significantly lower expression of RUNX2 and VEGFA after 
14 days. The actual concentration values are low, and it is difficult to assess whether this would result in a physio-
logical difference, although this incidence coincides with inferior trabecular connectivity. The lower RUNX2 and 
VEGFA values could be explained in 2 ways., Firstly, L-PRF membranes might alter the distinct pattern of growth 
factor kinetics, as shown in rabbit bone healing by Zhang et al.34 and Li et al.35. A clinical study by Eren et al.36 also 
found decreased values of early bone repair markers upon L-PRF application. These researchers hypothesized 
that the healing process in the L-PRF treated group was already in an advanced phase, requiring less biomarkers. 
A last explanation is that growth factors which are released from L-PRF could interfere with the expression of 
growth factors in the host tissue by means of inhibition. This might either be because the growth factors released 
from L-PRF are already at the needed level, so no additional production is necessary by the host tissue. Previous 
studies investigating application of recombinant growth factors37,38 have shown that the dose or release kinet-
ics themselves might actually inhibit bone formation. Unfortunately, further research, including measuring the 
protein levels of the investigated growth factors, was not possible due to the limited availability of sample tissue.
Along with the short term effects of L-PRF treatment, our study provided also some insights into the wound 
healing in early stages of bone formation, in terms of volumetric changes during bone defect repair and bone 
neoformation in the cortical and in the medullar bone respectively. We argue that our findings are relevant for 
future L-PRF studies with animal models. Approximately 60% of the bone defect was healed at the cortical bone 
level, irrespective of the treatment. Indeed, a bone bridge was not formed by the end of the experiment. Although 
this seems to favour performing long-term studies, our observed difference in trabecular structure would not 
have been observed in studies which solely focus on longer healing times. Similarly, the degree of anisotropy and 
the fractal dimension, 2 parameters closely related to the bone structure, had statistically significant decreased 
values (p < 0.05) after 14 days compared to the 7 days group, but increased again in the period leading up to 28 
days. This highlights the importance of investigating the bone healing process at early time points. These findings 
show that the early healing period is of critical importance during the bone healing. Also in terms of rabbit behav-
ior, rabbits start to be more mobile 7 days post-surgery, increasing the probability of membrane dislodgement. 
The aforementioned effects indicate that future studies should consider both short-term and long-term effects, 
and consider placement of barriers that promote the retention of the L-PRF membranes.
In the medullar region, the duration of healing was also the main factor that influenced bone regeneration. In 
contrast with the cortical area, most of the parameters reached significantly higher values after 14 days healing: 
BV; BV/TV; BS; BS/BV; BS/TV; Tb.N i.S. This indicates that bone healing is processed differently in the medullar 
region, in which greater BV/TV up to 16% was observed after 14 days of healing reducing to 5–10% thereafter. 
The cellular metabolic activity is likely to be at its optimum at 2 weeks healing since the bone morphological 
parameters are not stable and decreased thereafter.
This rabbit model encountered several limitations that jeopardise a full understanding of the effects of L-PRF 
treatment, such as the lack of fixation devices to stabilize the clot and potential bone damage due to high mobility 
of the animals especially after the 1st week. As mentioned above, the anatomy of the tibia does not favour reten-
tion of the L-PRF membrane. Because of the disruption of blood vessels in the defect, factors released from L-PRF 
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only might have a paracrine effect. Hence, if the membrane is slightly displaced, the factors released by L-PRF are 
diluted over a volume that is larger than the created defect.
Furthermore, measuring bone morphometric parameters by μ CT only indirectly assesses the strength, and 
hence the functionality of the bone. The results are sensitive to the selection of the regions of interest. Technologies 
using higher resolution are currently being developed and enable accurate measurements for bone microstructure 
in small volumes, and allow to adequately characterize the bone composition (discrimination between bone tis-
sue and adipose tissue, cartilage and bone, vasculature, etc. via the use of contrast agents). Moreover, many μ CT 
parameters show great variability between the individual rabbits, hampering statistical analysis. Further studies 
should therefore focus on accurate methods to describe, amongst others, bone mineral properties for cortical and 
medullary areas of non-critical sized bone defects. A further improvement could include a description of the per-
meability modification in these bone microenvironments, since this is likely an important parameter governing 
healing kinetics. Finally, the effects of L-PRF are expected to be more pronounced in a study that uses rabbits with 
systemic diseases that interfere in bone and wound healing, such as diabetes and osteoporosis.
Despite clear evidence of L-PRF-mediated bone healing in clinical studies and case reports, animal studies 
often fail to confirm this. Since the protocol for L-PRF production was mainly developed for human use, transla-
tion to other species is difficult. This leads to variation in protocols and experimental design, on top of the already 
present differences in biology and physiology.
In conclusion, L-PRF did not enhance bone tissue repair of non-critical size defects in rabbit tibia during 
our 4 week experiment. Its presence did promote microarchitectural changes related to connectivity network 
(Tb.Pf) during the healing process. Within the first 2 weeks, L-PRF had an adverse effect on the trabecular con-
nectivity. This period is followed by accelerated improvement of the trabecular connectivity between 2 and 4 
weeks. Similarly, mRNA expressions also suggest decreased healing dynamics at 14 days of healing when L-PRF 
is applied. The reasons for these observations are subject to further research.
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